Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.9
Journals
JCM
Special Issues
Thoracic Radiochemoimmunotherapy for Non-Small Cell Lung Cancer (NSCLC): Evolving Techniques...
jcm-logo
Submit to Special Issue Submit Abstract to Special Issue Review for JCM Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Thoracic Radiochemoimmunotherapy for Non-Small Cell Lung Cancer (NSCLC): Evolving Techniques and Clinical Applications

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 5 October 2026 | Viewed by 990

Special Issue Editor

Dr. Franz Zehentmayr

E-Mail Website
Guest Editor
Department of Radiation Oncology, Paracelsus Medical University, Salzburg, Austria
Interests: radiotherapy; lung cancer; real world data; IMRT; translational radiation biology

Special Issue Information

Dear Colleagues,

Thoracic radiotherapy is a cornerstone in the treatment of lung cancer patients. With rapid advancements in imaging technologies and precision-based radiotherapy techniques, modern oncology continues to evolve toward more individualized and effective and less invasive care. This Special Issue will cover the most clinically relevant topics in the field of NSCLC with respect to radical radiation treatment combined with immunochemotherapy.

Individualized approaches in the context of tailored therapies rely on sophisticated radiation technologies combined with translational molecular research. Hence, with a technical focus, this Special Issue will place emphasis on the integration of artificial intelligence, functional imaging (PET-CT), stereotactic radiation techniques, particle therapy for centrally located tumors, and MRT as a new image-guidance modality.

We welcome articles presenting findings from original research, clinical trials, real-world data, and reviews that reflect the latest trends and challenges radiation-based therapies, ultimately contributing to improved patient outcomes.

Dr. Franz Zehentmayr
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • radiotherapy
  • radiology
  • oncology
  • non-small cell lung cancer
  • real-world data
  • immunotherapy
  • radiation dose escalation

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 1152 KB  
Article
MLR and dMLR Predict Locoregional Control and Progression-Free Survival in Unresectable NSCLC Stage III Patients: Results from the Austrian Radio-Oncological Lung Cancer Study Association Registry (ALLSTAR)
by Alexandra Hochreiter, Markus Stana, Marisa Klebermass, Elvis Ruznic, Brane Grambozov, Josef Karner, Martin Heilmann, Danijela Minasch, Ayurzana Purevdorj, Georg Gruber, Raphaela Moosbrugger, Falk Röder and Franz Zehentmayr
J. Clin. Med. 2025, 14(24), 8876; https://doi.org/10.3390/jcm14248876 - 15 Dec 2025
Viewed by 693
Abstract
Background: As demonstrated by the PACIFIC trial, biomarker-driven patient selection is crucial. While treatment based on programmed death ligand-1 (PD-L1) and mutational status have become routine, tests for biomarkers available from pretherapeutic blood samples are currently a topic of scientific interest. Methods [...] Read more.
Background: As demonstrated by the PACIFIC trial, biomarker-driven patient selection is crucial. While treatment based on programmed death ligand-1 (PD-L1) and mutational status have become routine, tests for biomarkers available from pretherapeutic blood samples are currently a topic of scientific interest. Methods: This analysis was conducted on patients from the ALLSTAR RWD study, which is a nationwide, prospective registry for inoperable non-small cell lung cancer (NSCLC) stage III. Patients were amenable if they had a full routine pre-treatment blood sample, from which the following biomarkers were extracted: neutrophil-to-lymphocyte ratio (NLR), derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR), derived monocyte-to-lymphocyte ratio (dMLR) and lactate dehydrogenase (LDH) levels. The intention was to find a cutoff for each of these biomarkers to predict locoregional control (LRC), progression-free survival (PFS) and overall survival (OS). Results: MLR and dMLR demonstrated their predictive potential with cutoff values of 0.665 and 0.945, respectively. Stratifying the whole cohort by means of these cutoffs demonstrated significantly better locoregional control for patients below the threshold, both in the whole cohort (N = 175; 55.7% vs. 75.5%; p-value = 0.018) and in the Durvalumab subgroup (N = 106; 57.5% vs. 77.3%; p-value = 0.030). Similar findings were observed for PFS in the whole cohort (N = 175; 20.5% vs. 56.1%; p-value p < 0.001) and in the Durvalumab subgroup (N = 106; 31.2% vs. 64.6%, p-value < 0.001). dMLR could also significantly predict PFS (N = 173; 17.4% vs. 56.3%; p-value < 0.001), which was corroborated in the Durvalumab subgroup (N = 108; 23.1% vs. 64.1%; p-value = 0.003). Conclusions: This explorative analysis demonstrates the predictive potential of MLR and dMLR for LRC and PFS. These blood biomarkers can be readily integrated into clinical routines since they are easily available. Full article
(This article belongs to the Special Issue Thoracic Radiochemoimmunotherapy for Non-Small Cell Lung Cancer (NSCLC): Evolving Techniques and Clinical Applications)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop